% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lohner:296171,
      author       = {V. Lohner and L. Perna and B. Schöttker$^*$ and R.
                      Perneczky and M. Kliegel and H. Brenner$^*$ and U. Mons},
      title        = {{A}ssociations of biomarkers of neurodegenerative diseases
                      with mild neurocognitive disorder in a cohort of patients
                      with stable coronary heart disease},
      journal      = {Alzheimer's and dementia},
      volume       = {20 Suppl 8},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2025-00098},
      pages        = {e095214},
      year         = {2024},
      note         = {Developing Topics: Poster presentation},
      abstract     = {Coronary heart disease (CHD) is a well-known risk factor
                      for cognitive impairment and dementia, and blood biomarkers
                      of neurodegenerative diseases may be utilised to identify
                      people at higher risk of cognitive decline. Here, we aimed
                      to investigate prospective associations between these
                      biomarkers and mild neurocognitive disorder (MiND) after a
                      follow-up of ten years in patients with stable CHD, and
                      potential effect modification by hypercholesterolemia and
                      ApoE genotype.Biomarkers of neurodegenerative diseases
                      (glial fibrillary acidic protein (GFAP), neurofilament light
                      chain (NfL), and phosphorylated tau181 (p-tau181)) were
                      measured in baseline blood serum samples using the
                      Single-Molecule Array (Simoa) Technology (Quanterix, USA) in
                      a subset (n = 363) of a cohort of patients with stable CHD.
                      MiND was defined as scores ≤ 21.8 on the Cognitive
                      Telephone Screening Instrument (COGTEL).
                      Hypercholesterolemia was categorised into none (normal total
                      cholesterol (TC) levels without statin use), normal TC
                      levels with statin use, or increased TC levels independent
                      of statin use. We evaluated prospective associations of
                      biomarkers of neurodegenerative disease with MiND using
                      multivariable logistic regression models, adjusted for age,
                      sex, study centre, hearing impairment, and comorbidities. We
                      additionally checked for biomarker×ApoE genotype and
                      biomarker×hypercholesterolemia interactions.At follow-up,
                      55 $(15.2\%)$ patients had developed MiND. Higher levels of
                      NfL were associated with increased risks of developing MiND
                      (OR $(95\%-CI)$ per SD increase: 1.44 (1.01-2.04)).
                      Associations of p-tau181 with MiND were depending on
                      hypercholesterolemia, but not on ApoE genotype. Higher
                      levels of p-tau181 were associated with lower odds of
                      developing MiND in patients without hypercholesterolemia (OR
                      $(95\%-CI)$ per SD increase: 0.09 (0.01-0.39)) and higher
                      odds of developing MiND in patients with increased TC levels
                      (OR $(95\%-CI)$ per SD increase: 7.83 (1.72-103.20)), but
                      not in patients with normal TC levels using statins. Levels
                      of GFAP were not associated with MiND.Preliminary analyses
                      suggest that NfL and p-tau181 predict MiND after ten years
                      in patients with stable CHD, and that the association of
                      p-tau181 with MiND was modified by hypercholesterolemia.
                      This might imply that a deterioration in cognitive
                      performance in this population might be halted through early
                      management of hypercholesterolemia, however, more research
                      is warranted.},
      subtyp        = {Other},
      keywords     = {Humans / Male / Female / Aged / Biomarkers: blood / tau
                      Proteins: blood / Cognitive Dysfunction: blood / Coronary
                      Disease: blood / Hypercholesterolemia: blood / Glial
                      Fibrillary Acidic Protein: blood / Prospective Studies /
                      Middle Aged / Neurofilament Proteins: blood /
                      Apolipoproteins E: genetics / Risk Factors / Genotype /
                      Biomarkers (NLM Chemicals) / tau Proteins (NLM Chemicals) /
                      Glial Fibrillary Acidic Protein (NLM Chemicals) /
                      Neurofilament Proteins (NLM Chemicals) / neurofilament
                      protein L (NLM Chemicals) / Apolipoproteins E (NLM
                      Chemicals)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39783714},
      doi          = {DOI:10.1002/alz.095214},
      url          = {https://inrepo02.dkfz.de/record/296171},
}